BÜHLMANN IB*Doc*® references

- Weber *et al Poster at UEGW 2015*. Validation of a smartphone-based patient monitoring system measuring calprotectin as the therapy follow-up marker.
  "The performance of the smartphone-based IB*Doc* home testing system is comparable to professional, laboratory based methods". Uses BÜHLMANN IB*Doc* and BÜHLMANN fCAL® ELISA

- Parr *et al Poster at BSG 2016 PTH-054*. Home-testing of faecal calprotectin using the IB*Doc*™ system: a comparative pilot study
  ''85% of respondents preferred the IBDoc test over other methods''. Uses BÜHLMANN IB*Doc* and BÜHLMANN fCAL® ELISA

- Elsafi. G *et al UEGW 2017*. Cost effective of IBDoc as a surrogate marker of mucosal healing in IBDF patients post induction of biological agents.

  "In total 53 clinical visits and 62 colonoscopies were saved….. this study demonstrate a significant cost effectiveness of using IBDoc faecal calprotectin post induction of anti-TNF therapy as well as reducing the waiting time for both clinic visits and colonoscopies". Uses BÜHLMANN IB*Doc*

- Raker. J *et al ECCO 2017 P599*. Home testing for faecal calprotectin: follow-up results from the first UK trial.

  "A negative fCAL (<100µg/g) by either method is a useful test to exclude a flare within four months……." Uses BÜHLMANN IB*Doc* and BÜHLMANN fCAL® ELISA

- Fitzgerald. D *et al. ECCO 2017 N804*. An evaluation of patient satisfaction with IB*Doc* calprotectin home test system.

  "Calprotectin home testing using a smartphone as measuring system was very well received among the tested users (100% satisfaction). IBDoc offers patient empowerment for IBD patients who can remotely monitor their disease from the convenience of their own home". Uses BÜHLMANN IB*Doc*

- Heida. A *et al. ECCO 2017 P374*. Home or hospital-based analysis of stool calprotectin: assessing two methods for monitoring inflammatory bowel disease.

  "80% of all paired measurements were concordant". Uses BÜHLMANN IB*Doc* and BÜHLMANN fCAL® ELISA

- Ungar. B *et al ECCO 2017 P181.* Home smart-phone based measurement of fecal calprotectin by IBD patients: correlation with laboratory assay and applicability as patient-friendly monitoring tool.

  "the results of the home fecal calprotectin test (IBDoc) correlate well with values-ranges obtained using conventional lab-based calprotectin test. Smart-phone based fecal calprotectin test may be a useful patient-friendly tool for monitoring of IBD patients at home, with minimal interference to their routine." Uses BÜHLMANN IB*Doc* and BÜHLMANN Quantum Blue® fCAL

- Hejl. J *et al 2018 Practical Laboratory Medicine*. Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis.
  "We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL® turbo". Uses BÜHLMANN IB*Doc* and fCAL turbo®

- Heida. A *et al Clinical Gastroenterology and Hepatology 2017*. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring Inflammatory Bowel Disease Activity.

  "Spearman's rank correlation coefficient was 0.94 for results obtained by IBDoc vs Quantum Blue and 0.85 for results obtained by IBDoc vs ELISA". Uses BÜHLMANN IB*Doc,* BÜHLMANN fCAL ELISA and BÜHLMANN Quantum Blue® fCAL

- Bello. C *et al Digestive and Liver Disease 2017*. Usability of a home-based test for measurement of fecal calprotectin in asymptomatic IBD patients.

  "Usability scores for the home-based test were high. There was a very good correlation with the centrally measured FC by ELISA". Uses BÜHLMANN IB*Doc*

- Avery. P *et al ECCO 2018*. IBDoc self-care/Point of care Calprotectin Test: Early value in a district general hospital IBD service.
  "IBDoc adds value to patient care; it enhances the patient's journey allowing quick treatment decisions to be made saving at least one hospital admission during this small trial". Uses BÜHLMANN IB*Doc*

- Wei. S *et al ECCO 2018*. Patient's performance and feedback using home test faecal calprotectin as an objective reported outcome.
  "Correlation between the Quantum Blue test and the IBDoc results was good. Patients preferred to use the home test system for their disease monitoring"

- Moore. A *et al ECCO 2018*. Home based faecal calprotectin testing. A Canadian user performance evaluation study of IBDoc.
  "FC measurements produced by patients with IBDoc were strongly correlated with the standard FC ELISA measurements. Patients found the IBDoc home kit easy to use and a product they would like to use in the future"

- Walsh. A *et al ECCO 2018*. New defined calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis.
  Uses BÜHLMANN IB*Doc*

- Walsh. A *et al Journal of Crohns and Colitis 2018*. Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in Ulcerative colitis. A prospective analysis.
  "Correlation between FCal and symptoms in UC is weak. In contrast, the correlation between FCal and endoscopic or histological activity is strong".

- Wong. A *et al CDDW 2018*. Home based fecal calprotectin testing: A Canadian user performance study of IBDoc.
  "97% agree that they understood the instructions on the App with 85% agreeing that they were willing to use the home kit in the future"

- Wei. S *et al Intestinal Research Journal 2018*. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring.
  "96% of patients were satisfied with the home test…. And 71% of patients preferred the home test method to monitor their disease condition" Uses BÜHLMANN IB*Doc* and BÜHLMANN Quantum Blue® fCAL

- Heida. A *et al. J of Gastroenterology and Hepatology 2017*. Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity
  "We found sufficient agreement between the home used lateral flow test and the hospital-based ELISA test in the lower ranges of calprotectin to use this new test for telemonitoring of patients with asymptomatic IBD" Uses BÜHLMANN fCAL® ELISA , Quantum Blue® fCAL and IB*Doc*®

- Piekkala. M *et al. Journal of Pediatric Gastroenterology and Nutrition 2018*. Fecal calprotectin test performed at home: A prospective study of pediatric patients with inflammatory bowel disease.
  "PIBD patients and their families were interested in FC home monitoring and willing to adopt testing as a part of their disease management, but this approach requires thorough guidance"

- Walmsley. R *et al ECCO 2019*. A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBD*smart* and IB*Doc*® in the care of inflammatory bowel disease patients.
  "Use of IBD*smart* with IB*Doc* in routine clinical care of IBD patients over 12 months is acceptable, usable and non-inferior to standard clinic-based care"

- Haisma. S *et al PLOSONE 2019*. Head-to-head comparison of three stool calprotectin tests for home use.
  "The IB*Doc* smartphone application out-performed the others in terms of error-friendliness and system usability"

- Moore. A *et al Inflam Bowel Dis 2019*. IBDoc Canadian User Performance Evaluation.
  "85% of patients strongly agreeing that they were willing use the home kit in the future. The IBDoc and ELISA measurement comparison showed an 88% agreement across all values. There were no false positives or negatives using qualitative comparison"

- McCombie. A *et al Inflam Bowel Dis 2019.* A Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients.
  "Remote symptom and fecal calprotectin monitoring is effective and acceptable. It also reduces the need for face-to-face outpatient appointments. Patients with mild-to-moderate disease who are not new diagnoses are ideal for this system"

- Orfanoudaki. E *et al UEGW 2019*. The real world use of fecal calprotectin home testing in patients with IBD under maintenance treatment with adalimumab.
  "Our results confirm the important role of consecutive FC measurements at home, in combination with the endoscopic evaluation for the optimization of treatment in IBD patients receiving maintenance treatment with adalimumab"

- Avery. P *et al ECCO 2020.* IBDoc faecal calprotectin self-test a retrospective audit in a District General Hospital.
  "This information helps separate well from unwell patients, offering further opportunities to promote supported self-management in people with IBD and prioritisation of clinic appointments.

- Ostlund. I *et al Scandinavian Journal of Gastroenterology 2020*. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment A randomized controlled trial on patients with inflammatory bowel disease.

- Jaghult. S *et al ECCO 2020.* IBD Home at GHP Stockholm Gastro Center in Sweden.
  "Patients that are using the IBD Home experience the tool to be easy to use"

- Sugrue. K *et al ECCO 2020*. An evaluation of the impact of IB*Doc*® in clinical practice 5 years after introduction.
  "It is central to facilitating a fast track system for patients which results in better outcomes for patients. IB*Doc* facilitates better allocation of resources and results in cost savings"

- *Gastroenterology Today Winter 2020*. Delivering the Digital Future Today.
  "The IBDoc has the potential to transform clinical care pathways, reduce clinical admissions, reduce the need for clinic appointments and save costs by intervening quickly to stop disease progression and the requirement for more costly interventions".

- D'Amico F *et al. Journal of Clinical Medicine 2020*. Setting up a virtual clinic in inflammatory Bowel Diseases. A literature review and Nancy experience.
  " The IBDoc® is a simple tool to use and high satisfaction is found among IBDoc® users. IBD patients should be adequately informed and trained on the use of this test. FC home tests are an additional value for e-health approach in IBD patients. In the near future, these tests could allow not only tight monitoring of IBD patients but also their greater involvement in disease management."

- Jere. M *et al. British Medical Journal 2021*. Point of Care faecal calprotectin testing in patients with paediatric inflammatory bowel disease during the COVID-19 pandemic.
  "85% stated that they preferred the home test to the laboratory testing method. Home calprotectin tests were useful in guiding clinical management during a time when laboratory testing was less available. They may offer benefits as part of routine paediatric IBD monitoring to help target appointments and reduce unnecessary hospital attendances in the future."

- Jogendran. R *et al. Journal of Canadian Gastroenterology 2021*. Optimizing maternal and neonatal outcomes in IBD: Tight control management of IBD during pregnancy – Pilot study.
  "A combination of both clinical scores and objective disease markers may better predict disease relapse compared to either clinical scores or objective markers in isolation. A home point-of-care FCP test is feasible among pregnant patients with IBD"

- Orfanoudaki. E *et al. European Journal of Gastroenterology and Hepatology 2021.* Real-life utility and diagnostic accuracy of a home-performed faecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under maintenance treatment with adalimumab.
  "FC home test (IB*Doc*) is a valuable tool with high compliance rates that performs better than other biomarkers in predicting disease endoscopic activity"

- Edwards. D *et al. et al. ECCO virtual 2021 P518*. Comparison of clinical performance of fecal calprotectin of laboratory methods with lateral flow based POC and home tests.
  "The improvement in FC testing compliance with rapid home testing kit compared to laboratory-based testing illustrates the benefit of adopting home testing as the standard in future"

- Reinhard. C *et al. ECCO 2024 P473*. Compliance with faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory-based testing pre-COVID.
  "The results presented here show that the four BÜHLMANN assays measure fecal calprotectin highly comparably and show an excellent clinical performance. This allows for the use of the methods interchangeably, depending on the needs of the patients and their care team."

- Khan. S *et al. BSG 2025*. Impact of home-based faecal calprotectin testing in IBD patients: Environmental sustainability and timely disease monitoring.

"Home based testing saved 1,658 miles (average 10.4 miles per patient) …. Assessment times averaged 1.7 days, significantly faster than traditional methods."

- Nixon. E *BSG 2025*. Enhancing IBD Management: The benefits and challenges of Home Faecal Calprotectin Testing for Patients and Clinicians.
  "76% of patients reported that the home testing process was 'easy' or 'somewhat easy' reflecting high levels of accessibility and patient satisfaction. Of those surveyed, 62% expressed a preference for POC testing over traditional laboratory methods citing its convenience and time efficiency."